CAJ | 학술논문

目的探讨18F-FDG PET/CT评价弥漫性大B细胞淋巴瘤(DLBCL)患者化疗中期治疗反应的价值.方法 DLBCL初诊患者53例,采用环磷酰胺+阿霉素+长春新碱+泼尼松(CHOP)或利妥苷单克隆抗体+环磷酰胺+阿霉素+长春新碱+泼尼松(R-CHOP)方案化疗,分别于化疗前和化疗中期(4个疗程后)进行18F-FDG PET/CT显像.根据肿瘤对化疗的反应将病例分为完全反应组、部分反应组和无反应组,比较3组患者的完全缓解率.用SPSS 13.0软件进行统计学分析,完全缓解率的比较用χ2检验.结果完全反应组、部分反应组和无反应组的临床完全缓解率分别为88.5%(23/26)、73.3%(11/15)和8.3%(1/12),3组间差异有统计学意义(χ2=23.548,P=0.000).完全反应组、部分反应组的完全缓解率高于无反应组(χ2=22.656,P=0.000和χ2=11.407,P=0.001).结论 DLBCL患者化疗中期18F-FDG PET/CT显像有助于预测其化疗疗效.
목적 탐토18F-FDG PET/CT평개미만성대B세포림파류(DLBCL)환자화료중기치료반응적개치.방법 DLBCL초진환자53례,채용배린선알+아매소+장춘신감+발니송(CHOP)혹리타감단극륭항체+배린선알+아매소+장춘신감+발니송(R-CHOP)방안화료,분별우화료전화화료중기(4개료정후)진행18F-FDG PET/CT현상.근거종류대화료적반응장병례분위완전반응조、부분반응조화무반응조,비교3조환자적완전완해솔.용SPSS 13.0연건진행통계학분석,완전완해솔적비교용χ2검험.결과 완전반응조、부분반응조화무반응조적림상완전완해솔분별위88.5%(23/26)、73.3%(11/15)화8.3%(1/12),3조간차이유통계학의의(χ2=23.548,P=0.000).완전반응조、부분반응조적완전완해솔고우무반응조(χ2=22.656,P=0.000화χ2=11.407,P=0.001).결론 DLBCL환자화료중기18F-FDG PET/CT현상유조우예측기화료료효.
Objective To explore the value of 18F-FDG PET/CT on the assessment of chemotherapy response in patients with diffuse large B-cell lymphoma (DLBCL). Methods 18F-FDG PET/CT was performed before and after 4 cycles of chemotherapy( R-CHOP or CHOP protocol) in 53 patients with DLBCL. The patients were divided into 3 groups: complete response group, partial response group and no response group. The therapeutic response was assessed by comparing post-treatment 18F-FDG PET/CT with pre-treatment PET/CT. Complete remission (CR) rate at the end of chemotherapy was calculated. χ2 test was performed with software SPSS 13.0. Results CR rates of complete response group, partially response group and no response group were 88.5% (23/26), 73.3% (11/15) and 8.3% (1/12), respectively (χ2=23.548, P=0.000). CR rates of the complete and partially response groups were significantly higher than those of no response group (χ2=22.656, P=0.000; χ2=11.407, P=0.001). Conclusion 18F-FDG PET/CT may be useful for the assessment of chemotherapy response in DLBCL.